Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
efavirenz
Bristol-Myers Squibb Pharma EEIG
J05AG03
efavirenz
Antivirals for systemic use
HIV Infections
Sustiva is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older.Sustiva has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Sustiva.
Revision: 48
Authorised
1999-05-28
85 B. PACKAGE LEAFLET Medicinal product no longer authorised 86 PACKAGE LEAFLET: INFORMATION FOR THE USER SUSTIVA 50 MG HARD CAPSULES efavirenz READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What SUSTIVA is and what it is used for 2. What you need to know before you take SUSTIVA 3. How to take SUSTIVA 4. Possible side effects 5. How to store SUSTIVA 6. Contents of the pack and other information 1. WHAT SUSTIVA IS AND WHAT IT IS USED FOR SUSTIVA, which contains the active substance efavirenz, belongs to a class of antiretroviral medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is an ANTIRETROVIRAL MEDICINE THAT FIGHTS HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) infection by reducing the amount of the virus in blood. It is used by adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. Your doctor has prescribed SUSTIVA for you because you have HIV infection. SUSTIVA taken in combination with other antiretroviral medicines reduces the amount of the virus in the blood. This will strengthen your immune system and reduce the risk of developing illnesses linked to HIV infection. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SUSTIVA DO NOT TAKE SUSTIVA IF YOU ARE ALLERGIC to efavirenz or any of the other ingredients of this medicine (listed in section 6). Contact your doctor or pharmacist for advice. IF YOU HAVE SEVERE LIVER DISEASE. IF YOU HAVE A HEART CONDITION, SUCH AS CHANGES IN THE RHYTHM OR RATE OF THE HEARTBEAT Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT SUSTIVA 50 mg hard capsules SUSTIVA 100 mg hard capsules SUSTIVA 200 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION SUSTIVA 50 mg hard capsules Each hard capsule contains 50 mg of efavirenz. Excipient with known effect Each hard capsule contains 28.5 mg of lactose (as monohydrate). SUSTIVA 100 mg hard capsules Each hard capsule contains 100 mg of efavirenz. Excipient with known effect Each hard capsule contains 57.0 mg of lactose (as monohydrate). SUSTIVA 200 mg hard capsules Each hard capsule contains 200 mg of efavirenz. Excipient with known effect Each hard capsule contains 114.0 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule SUSTIVA 50 mg hard capsules Dark yellow and white, printed with "SUSTIVA" on the dark yellow cap and "50 mg" on the white body. SUSTIVA 100 mg hard capsules White, printed with "SUSTIVA" on the body and "100 mg" on the cap. SUSTIVA 200 mg hard capsules Dark yellow, printed with "SUSTIVA" on the body and "200 mg" on the cap. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS SUSTIVA is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV- 1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. SUSTIVA has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm 3 , or after failure of protease inhibitor (PI) containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after failure of regimens containing SUSTIVA. Medicinal product no longer authorised 3 For a summary of clinical and pharmacodynamic information, see section 5.1. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Therapy should be initiated by a physician experienc Lesen Sie das vollständige Dokument